![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Active Filter(s):
Details:
With this funding, VLPT aims to further accelerate the research and development of a cancer treatment vaccine as well as prophylactic vaccines including VLPM01, against malaria, dengue, etc. and move into clinical trials at the earliest date possible.
Lead Product(s): VLPM01
Therapeutic Area: Infections and Infectious Diseases Product Name: VLPM01
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Nobelpharma
Deal Size: $21.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing December 27, 2021